Metadata
Show full item recordShare this item!
The role of the endocannabinoid system as a therapeutic target for autism spectrum disorder: Lessons from behavioral studies on mouse models
MARSICANO, Giovanni
Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
MARSICANO, Giovanni
Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
< Reduce
Neurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
Language
EN
Article de revue
This item was published in
Neuroscience and Biobehavioral Reviews. 2022-01, vol. 132, p. 664-678
English Abstract
Recent years have seen an impressive amount of research devoted to understanding the etiopathology of Autism Spectrum Disorder (ASD) and developing therapies for this syndrome. Because of the lack of biomarkers of ASD, ...Read more >
Recent years have seen an impressive amount of research devoted to understanding the etiopathology of Autism Spectrum Disorder (ASD) and developing therapies for this syndrome. Because of the lack of biomarkers of ASD, this work has been largely based on the behavioral characterization of rodent models, based on a multitude of genetic and environmental manipulations. Here we highlight how the endocannabinoid system (ECS) has recently emerged within this context of mouse behavioral studies as an etiopathological factor in ASD and a valid potential therapeutic target. We summarize the most recent results showing alterations of the ECS in rodent models of ASD, and demonstrating ASD-like behaviors in mice with altered ECS, induced either by genetic or pharmacological manipulations. We also give a critical overview of the most relevant advances in designing treatments and novel mouse models for ASD targeting the ECS, highlighting the relevance of thorough and innovative behavioral approaches to investigate the mechanisms acting underneath the complex features of ASD. © 2021Read less <
English Keywords
Autism
CB1r
Cannabinoids
Developmental disorders
Mouse models
Social behaviors
European Project
Neurocircuitry of endocannabinoid regulation of food intake
Development of pregnenolone derivatives as allosteric inhibitors of CB1 cannabinoid receptors for thetreatment of schizophrenia and psychotic syndromes
Development of pregnenolone derivatives as allosteric inhibitors of CB1 cannabinoid receptors for thetreatment of schizophrenia and psychotic syndromes
ANR Project
Dissection des mécanismes hypothalamiques impliqués dans la détection du statut nutritionnel et régulation de la prise alimentaire via les interactions entre mTORC1, les mélanocortines et les endocannabinoïdes. - ANR-13-BSV4-0006
Représentation sensorielle lors d'états psychotiques - ANR-16-CE37-0010
Recepteurs aux cannabinoides dans le codage visuel cortical - ANR-18-CE16-0001
Rôle du récepteur aux cannabinoïdes de type 1 mitochondriale dans les circuits hypothalamiques et son interaction avec la voie mTORC1 dans l'obésité. - ANR-18-CE14-0029
Bordeaux Region Aquitaine Initiative for Neuroscience - ANR-10-LABX-0043
Représentation sensorielle lors d'états psychotiques - ANR-16-CE37-0010
Recepteurs aux cannabinoides dans le codage visuel cortical - ANR-18-CE16-0001
Rôle du récepteur aux cannabinoïdes de type 1 mitochondriale dans les circuits hypothalamiques et son interaction avec la voie mTORC1 dans l'obésité. - ANR-18-CE14-0029
Bordeaux Region Aquitaine Initiative for Neuroscience - ANR-10-LABX-0043